TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

About this update from Tscan Therapeutics, Inc.

WALTHAM, Mass. , April 22, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of one abstract for oral presentation and four abstracts for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11 in Baltimore, MD as well as virtually. Oral Presentation Details: Title: Discovery of Tumor Reactive TCRs and Their Cognate Antigenic Targets via High-Throughput Functional Screening Presenter: Candace Perullo Abstract Number: 419 Session Title: Targeted Gene and Cell Therapy II Session Date/Time: Saturday, May 11 ; 10:15 a.m. - 12:00 p.m. Eastern Time Presentation Time: 11:15 - 11:30 a.m. Eastern Time Location: Room 318 -323 Poster Presentation Details: Title: Nonclinical Development of T-Plex Component TSC-204-A0101: A Natural TCR-T Cell Therapy for the Treatment of MAGE-A1- and HLA-A*01:01-Positive Cancers Presenter: Shazad Khokhar , Ph.D. Abstract Number: 834 Session Title: Wednesday Posters: Immune Targeting and Approaches with Genetically-Modified Cells and Cell Therapies Session Date/Time: Wednesday, May 8 ; 12:00 p.m. Eastern Time Location: Exhibit Hall Title: Non-Clinical Development of T-Plex Component TSC-201-B0702: A TCR-T Cell Therapy Directed to a Novel HLA-B*07:02 Restricted MAGE-C2 Epitope for the Treatment of Solid Tumors Presenter: Hannah Bader , Ph.D. Abstract Number: 835 Session Title: Wednesday Posters: Immune Targeting and Approaches with Genetically-Modified Cells and Cell Therapies Session Date/Time: Wednesday, May 8 ; 12:00 p.m. Eastern Time Location: Exhibit Hall Title: Trial in Progress: A Phase 1, First in Human Clinical Trial for T-Plex, a Multiplexed, Enhanced T Cell Receptor-Engineered T Cell Therapy (TCR-T) for Solid Tumors Presenter: Dawn Pinchasik , M.D. Abstract Number: 1900 Session Title: Friday Posters: Cell Therapy and Cell-Based Gene Therapy Trials Session Date/Time: Friday, May 10 ; 12:00 p.m. Eastern Time Location: Exhibit Hall Title: Trial in Progress: A Phase 1 Trial of TSC-100 and TSC-101, Engineered T Cell Therapies That Target Minor Histocompatibility Antigens to Eliminate Residual Disease After Hematopoietic Cell Transplantation Presenter: Michelle Matzko , M.D., Ph.D. Abstract Number: 1901 Session Title: Friday Posters: Cell Therapy and Cell-Based Gene Therapy Trials Session Date/Time: Friday, May 10 ; 12:00 p.m. Eastern Time Location: Exhibit Hall A copy of the presentation materials will be added to the “ Publications ” section of the Company’s website at tscan.com once presentations have concluded. About TScan Therapeutics, Inc. TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company’s lead TCR-T candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T candidates for the treatment of various solid tumors. The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex therapeutic TCR-Ts for patients with a variety of cancers. Contacts Heather Savelle TScan Therapeutics, Inc. VP, Investor Relations857-399-9840 [email protected] Maghan Meyers Argot Partners 212-600-1902 [email protected] Source: TScan Therapeutics, Inc.

View stock analysis, news, and events for Tscan Therapeutics, Inc.